AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy. We report the characterization of AC220, a second-generation FLT3 inhibitor, a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Zarrinkar, Patrick P., Gunawardane, Ruwanthi N., Cramer, Merryl D., Gardner, Michael F., Brigham, Daniel, Belli, Barbara, Karaman, Mazen W., Pratz, Keith W., Pallares, Gabriel, Chao, Qi, Sprankle, Kelly G., Patel, Hitesh K., Levis, Mark, Armstrong, Robert C., James, Joyce, Bhagwat, Shripad S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2009
Schlagworte:
Myeloid Neoplasia
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2756206/
https://ncbi.nlm.nih.gov/pubmed/19654408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-05-222034
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge